Patents by Inventor Didier Mesangeau

Didier Mesangeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
    Patent number: 9035048
    Abstract: The invention relates to compounds of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with the activity of AMP-activated protein kinase (AMPK). Another object of the invention concerns the use of said compounds for enhancing glucose homeostasis, improving podocytopathy and/or decreasing the production of reactive oxygen species (ROS). The invention also relates to a method for in-vitro diagnosing diabetic nephropathy and a method for screening compounds that reduce podocytopathy, in each case by applying synaptopodin as biomarker.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 19, 2015
    Assignee: POXEL
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Didier Mesangeau, Samer Elbawab
  • Combination of insulin with triazine derivatives and its use for treating diabetes
    Patent number: 8980828
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: March 17, 2015
    Assignee: Poxel S.A.S.
    Inventors: Didier Mesangeau, Daniel Cravo, Annick Audet
  • Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases
    Patent number: 8937066
    Abstract: The invention relates to amino derivatives of dihydro-1,3,5-triazine, used for the treatment and/or prevention of diseases induced by ischemia and/or reperfusion, notably cardiac and renal complications.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: January 20, 2015
    Assignees: Poxel, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Didier Mesangeau, Daniel Cravo, Catherine Noe
  • Combination of triazine derivatives and insulin sensitisers
    Patent number: 8791115
    Abstract: The present invention relates to combinations of triazine derivatives and of insulin sensitizers.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 29, 2014
    Assignee: Poxel SAS
    Inventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
  • COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITISERS
    Publication number: 20140050786
    Abstract: The present invention relates to combinations of triazine derivatives and of insulin sensitisers.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicant: POXEL SAS
    Inventors: Gerard MOINET, Daniel CRAVO, Didier MESANGEAU
  • Combination of insulin with triazine derivatives
    Patent number: 8592370
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: November 26, 2013
    Assignee: Poxel S.A.S.
    Inventors: Didier Mesangeau, Daniel Cravo, Annick Audet
  • COMBINATION OF INSULIN WITH TRIAZINE DERIVATIVES AND ITS USE FOR TREATING DIABETES
    Publication number: 20130310312
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Application
    Filed: July 15, 2013
    Publication date: November 21, 2013
    Inventors: Didier MESANGEAU, Daniel CRAVO, Annick AUDET
  • Combination of triazine derivatives and insulin secretion stimulators
    Patent number: 8227465
    Abstract: The present patent application relates to novel combinations of a triazine derivative and of an insulin secretion stimulator.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 24, 2012
    Assignee: Poxel SAS
    Inventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
  • AMINO DERIVATIVES OF DIHYDRO-1,3,5-TRIAZINE USED IN THE TREATMENT OF ISCHEMIA AND/OR REPERFUSION RELATED DISEASES
    Publication number: 20120122873
    Abstract: The invention relates to amino derivatives of dihydro-1,3,5-triazine, used for the treatment and/or prevention of diseases induced by ischemia and/or reperfusion, notably cardiac and renal complications.
    Type: Application
    Filed: July 16, 2010
    Publication date: May 17, 2012
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), POXEL
    Inventors: Didier Mesangeau, Xavier Leverve, Daniel Cravo
  • COMBINATION OF A SODIUM-PROTON EXCHANGER INHIBITOR AND OF A DIHYDRO-1,3,5-TRIAZINE AMINE DERIVATIVE
    Publication number: 20120115872
    Abstract: The invention relates to a combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative which is useful for the treatment and/or prevention of pathologies induced by ischaemia and/or reperfusion, especially cardiac and renal complications.
    Type: Application
    Filed: June 18, 2010
    Publication date: May 10, 2012
    Applicant: Merck Patent GMBH
    Inventors: Didier Mesangeau, Daniel Cravo, Xavier Leverve
  • COMBINATION OF INSULIN WITH TRIAZINE DERIVATIVES AND ITS USE FOR TREATING DIABETES
    Publication number: 20110306543
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Application
    Filed: November 13, 2009
    Publication date: December 15, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Didier Mesangeau, Daniel Cravo, Annick Audet
  • COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITISERS
    Publication number: 20100285117
    Abstract: The present invention relates to combinations of triazine derivatives and of insulin sensitisers.
    Type: Application
    Filed: December 18, 2006
    Publication date: November 11, 2010
    Inventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
  • COMBINATION OF TRAZINE DERIVATIVES AND INSULIN SECRETION STIMULATORS
    Publication number: 20100233255
    Abstract: The present patent application relates to novel combinations of a triazine derivative and of an insulin secretion stimulator.
    Type: Application
    Filed: December 18, 2006
    Publication date: September 16, 2010
    Inventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
  • Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
    Patent number: 7767676
    Abstract: The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 3, 2010
    Assignee: Merck Sante
    Inventors: Gerard Moinet, Daniel Cravo, Liliane Doare, Micheline Kergoat, Didier Mesangeau
  • COMBINATION OF TRIAZINE DERIVATIVES AND PPARalpha AGONISTS
    Publication number: 20100159005
    Abstract: The present patent application relates to combinations of triazine derivatives and of PPAR? agonists.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 24, 2010
    Inventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
  • COMBINATION OF TRIAZINE DERIVATIVES AND HMG-COA REDUCTASE INHIBITORS
    Publication number: 20100158999
    Abstract: The present patent application relates to combinations of a triazine derivative with an HMG-CoA reductase inhibitor.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 24, 2010
    Inventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
  • Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
    Patent number: 7452883
    Abstract: The invention concerns compounds of general formula (I) wherein: R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. The compounds are useful in the treatment of pathologies related to the insulin-resistance syndrome.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: November 18, 2008
    Assignee: Merck Sante
    Inventors: Gerard Moinet, Daniel Cravo, Liliane Doare, Micheline Kergoat, Didier Mesangeau
  • Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
    Publication number: 20080108591
    Abstract: The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Applicant: MERCK SANTE
    Inventors: Gerard Moinet, Daniel Cravo, Liliane Doare, Micheline Kergoat, Didier Mesangeau
  • Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
    Publication number: 20080108619
    Abstract: The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.
    Type: Application
    Filed: October 30, 2007
    Publication date: May 8, 2008
    Applicant: MERCK SANTE
    Inventors: Gerard Moinet, Daniel Cravo, Liliane Doare, Micheline Kergoat, Didier Mesangeau
  • Bauhinia extracts
    Publication number: 20060188591
    Abstract: The present invention relates to an plant extract from Bauhinia species with hypoglycemic activity, which is characterized in being obtained from a Bauhinia species and to a method for producing the extract and the use of the extract in the treatment of diabetes type 2.
    Type: Application
    Filed: April 24, 2006
    Publication date: August 24, 2006
    Inventors: Herwig Buchholz, Corinna Wirth, Valerie Bicard-Benhamou, Deoclecio Carmo, Didier Mesangeau